Author:
Gomez-Escobar Elsa,Burlaud-Gaillard Julien,Visdeloup Clara,Silva Adeline Ribeiro E.,Coutant Pauline,Roingeard Philippe,Beaumont Elodie
Abstract
AbstractHepatitis C is a major threat to public health for which an effective treatment is available, but a prophylactic vaccine is still needed to control this disease. We designed a vaccine based on chimeric HBV–HCV envelope proteins forming subviral particles (SVPs) that induce neutralizing antibodies against HCV in vitro. Here, we aimed to increase the neutralizing potential of those antibodies, by using HBV–HCV SVPs bearing apolipoprotein E (apoE). These particles were produced by cultured stable mammalian cell clones, purified and characterized. We found that apoE was able to interact with both chimeric HBV–HCV (E1-S and E2-S) proteins, and with the wild-type HBV S protein. ApoE was also detected on the surface of purified SVPs and improved the folding of HCV envelope proteins, but its presence lowered the incorporation of E2-S protein. Immunization of New Zealand rabbits resulted in similar anti-S responses for all rabbits, whereas anti-E1/-E2 antibody titers varied according to the presence or absence of apoE. Regarding the neutralizing potential of these anti-E1/-E2 antibodies, it was higher in rabbits immunized with apoE-bearing particles. In conclusion, the association of apoE with HCV envelope proteins may be a good strategy for improving HCV vaccines based on viral envelope proteins.
Funder
Agence Nationale de Recherches sur le Sida et les Hépatites Virales
Conseil Régional du Centre-Val de Loire
Ligue Contre le Cancer
Publisher
Springer Science and Business Media LLC
Reference47 articles.
1. World Health Organization. Global Hepatitis Report, 2017 (World Health Organization, 2017). https://apps.who.int/iris/bitstream/handle/10665/255016/9789241565455-eng.pdf;jsessionid=97557CA9213CCC5D75D3D8BFC471FD77?sequence=1.
2. Asrani, S. K., Devarbhavi, H., Eaton, J. & Kamath, P. S. Burden of liver diseases in the world. J. Hepatol. 70, 151–171 (2019).
3. Roingeard, P. & Beaumont, E. Hepatitis C vaccine: 10 Good reasons for continuing. Hepatology 71, 1845–1850 (2020).
4. El-Serag, H. B. & Rudolph, K. L. Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 132, 2557–2576 (2007).
5. Simmons, B., Saleem, J., Hill, A. M., Riley, R. D. & Cooke, G. S. Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: A systematic review and meta-analysis. Clin. Infect. Dis. 62, 683–694 (2016).
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献